

- 2a - CJ Tralau-Stewart et al., UK Academic drug discovery, *Nature Rev. Drug Discov.* 2013, 13, 15; doi:[10.1038/nrd4200](https://doi.org/10.1038/nrd4200)
- 2b -H S Kirkegaard, F Valentin, Academic drug discovery centres: the economic and organisational sustainability of an emerging model, *DDT* Available online 19 June 2014, DOI: [10.1016/j.drudis.2014.06.011](https://doi.org/10.1016/j.drudis.2014.06.011)
- 2c - A A Toole, The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry, *Res. Policy* 2012, 41, 1; doi:[10.1016/j.respol.2011.06.004](https://doi.org/10.1016/j.respol.2011.06.004)
- 2d - JW Scannell, et al., Diagnosing the decline in pharmaceutical R&D efficiency, *Nature Rev. Drug Discov.* 2012, 11, 191; doi:[10.1038/nrd3681](https://doi.org/10.1038/nrd3681)
- 2e - M Goldman, The Innovative Medicines Initiative: A European Response to the Innovation Challenge, *Clinical Pharmacology & Therapeutics* 2012, 91, 418 doi:[10.1038/clpt.2011.321](https://doi.org/10.1038/clpt.2011.321)
- 2f - M Goldman, Reflections on the Innovative Medicines Initiative, *Nature Rev. Drug Discov.* 2011, 10, 321; doi:[10.1038/nrd3434](https://doi.org/10.1038/nrd3434)
- 2g - F Pammolli et al., The productivity crisis in pharmaceutical R&D, *Nature Rev. Drug Discov.* 2011, 10, 428 ; doi:[10.1038/nrd3405](https://doi.org/10.1038/nrd3405)
- 2h - M Williams, Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences? *JPET* 2011, 336, 3; doi: [10.1124/jpet.110.171751](https://doi.org/10.1124/jpet.110.171751)
- SM Paul et al., How to improve R&D productivity: the pharmaceutical industry's grand challenge, *Nature Rev. Drug Discov.* 2010, 9, 203; doi:[10.1038/nrd3078](https://doi.org/10.1038/nrd3078)
- 2i - R Kneller, The importance of new companies for drug discovery: origins of a decade of new drugs. *Nature Rev. Drug Discov.* 2010, 9, 867; doi:[10.1038/nrd3251](https://doi.org/10.1038/nrd3251)
- 2j - M R Barnes et al. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery, *Nature Rev. Drug Discov.* 2009, 8, 701; doi:[10.1038/nrd2944](https://doi.org/10.1038/nrd2944)
- 2k - B Hughes, Harnessing open innovation, *Nature Rev. Drug Discov.* 2009, 8, 344; [10.1038/nrd2891](https://doi.org/10.1038/nrd2891).
- 2l - B Munos, Lessons for 60 years of pharmaceutical innovation, *Nature Rev. Drug Discov.* 2009, 8, 959 doi:[10.1038/nrd2961](https://doi.org/10.1038/nrd2961)
- 2m - PG Wyatt, The emerging academic drug-discovery sector. *Future Med. Chem.* 2009, 1, 1013.
- 2n -CJ Tralau-Stewart, CA Wyatt, DE Kleyn, A Ayad, Drug discovery: new models for industry–academic partnerships, *Drug Discov Today* 2009, 14, 95. Doi:[10.1016/j.drudis.2008.10.003](https://doi.org/10.1016/j.drudis.2008.10.003)